Glycomine Develops Replacement Therapies For Rare Genetic Disorders
Rare genetic disorders are being discovered everyday and most of them do not have any FDA approved treatments. With no treatment modes available, these diseases can only be passed on to further generations. Worse still, is that lack of treatment can also claim lives in some cases? Glycomine, a San Francisco based company, has its focus on diseases of protein and lipid glycolysation,
Glycomine is currently working on replacing enzymes or substrates that can be delivered to the cells using advanced delivery methods. Currently in research or early pre clinical stages of developing therapies, Glycomine and its team have the potential and the drive to address rare genetic disorders like never before.